Popis Výživový doplnok obsahujúci karnozín-derivát karcinín, antiglykačný, deglykačný a antiagingový prípravok.
Inhibícia synergie medzi reakciami glykácie a oxidácie.
Zastavenie propagátorov vychytávania (glukóza, glyoxal atď.).
Inhibícia peroxidácie lipidov.
Chelatácia kovových iónov.
Protistarnúca starostlivosť o pokožku.
Vlastnosti Karcinín je stabilnejší ako karnozín, nie je napádaný enzýmom karnozinázou ani premieňaný na histidín. Rýchlo sa vstrebáva, odoláva žalúdočnému pH a peptidázam pokožky, séra a tkanív. Pôsobí v organizme dlhšie, čo umožňuje zlepšiť jeho účinnosť proti glykácii.
Zloženie Glycoless (dichlorhydrát karcinínu), Lithotame (Lithothamnion calcareum Areschoug, prášok zo stielky), stearát horečnatý, pikolinát chrómu, želatínová kapsula z rastlinného zdroja (E171).
Výživové hodnoty | Priemerné hodnoty na 1 kapsulu |
|---|
| Glycoless | 200 mg |
| Lithotame | 200 mg |
| Stearát horečnatý | 2 mg |
| Pikolinát chrómu | 1,66 mg |
Spôsob použitia 1 kapsula ráno nalačno.
Uchovávanie Uchovávajte pri teplote nepresahujúcej +25 °C.
Doba trvanlivosti v neporušenom balení: 36 mesiacov.
Formát Balenie obsahuje 15 kapsúl.
Kód: NOM
Bibliografia 1. "The role of carcinine treatment on glycolipid imbalance of overweight and obese woman", Palmieri B., Pepe V., Simas L.a.w., Granzoti R., Novak B., Wolpe R.e., Zilbert B., Yamaguchi E.m., Vadalà M., Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Surgical Clinic.
2. "A suplementação de carcinina e sua implicação na glicemia de jejum, hemoglobina glicada, insulina, frutosamina e perfil lipídico em mulheres com sobrepeso e obesidade: um ensaio clínico randomizado duplo-cego controlado por placebo". Simas, l.A.W.; Granzoti; r.; Novak, b; wolpe, r.E.; Zilbert, b.; Yamaguchi, e.M.
3. "L-Carnosine(-alanyl-L-histidine) and carcinine F-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidase activities", Mark A. Babizhayev, Marie-Christine Seguin, Jean Gueynej, Rima P. Evstigneeva, Elena A. Ageyeva and Galina A. Zheltukhinai, Moscow Helmholtz Research Institute of Eye Diseases, Russia, and IM.V. Lomonosov Institute of Fine Chemical Technology, Russia, Exsymol S.A.M., Monaco, Principaute de Monaco.
4. "Carcinine Has 4-Hydroxynonenal Scavenging Property and Neuroprotective Effect in Mouse Retina", Lea D. Marchette, Huaiwen Wang, Feng Li, Mark A. Babizhayev, Anne Kasus-Jacobi, Departments of Ophthalmology, Molecular Biology Proteomics Facility, and Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
5. "Investigating Carcinine Transport and the Expression Profile of Transporter Genes in Human Corneal Epithelial Cells", Studies on the Cornea and Lens, pp 131-144, Anne Kasus-Jacobi (Department of Pharmaceutical Sciences and Oklahoma Center for Neuroscience), Vibudhuta Awasthi (Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences), Mark A. Babizhayev (Innovative Vision Products Inc., Moscow, Russia), H. Anne Pereira (Departments of Pharmaceutical Sciences, Pathology, and Cell Biology and Oklahoma Center for Neuroscience, University of Oklahoma Health Sciences Center, Oklahoma City, USA).
6. "Treatment of Skin Aging and Photoaging with Innovative Oral Dosage Forms of Non-Hydrolized Carnosine and Carcinine", Research Article ,International Journal of Clinical Dermatology & Research (IJCDR), Babizhayev Mark A. (Innovative Vision Products, Inc).
7. "Advanced Glycation End-Products and Their Receptor- Mediated Roles: Inflammation and Oxidative Stress", Parisa Younessi, Ali Yoonessi, Iran J Med Sci, September 2011; Vol 36 N. 3.
8. A. Pegova, "Comp. Biochem. Physiol.", vol. 127, (2000). pp. 443-446.
